ASNS and acute lymphoblastic leukemia: The aspartate synthetase ASNS is a focus of clinical attention, because the imbalance of the expression of ASNS in children’s acute lymphoblastic leukemia (ALL) cells is considered to offset the impact of a first-line therapy for ALL that depletes asparagine (148–150).